Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen J Blake

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Experimental Hematology|April 24, 2012
Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine AStephen J Blake, Timothy P Hughes, A Bruce Lyons
Current Protocols in Cytometry|April 3, 2013
Flow cytometric analysis of cell division by dilution of CFSE and related dyesA Bruce Lyons, Stephen J Blake, Kathleen V Doherty
FASEB Bioadvances|October 11, 2021
OX40-targeted immune agonist antibodies induce potent antitumor immune responses without inducing liver damage in miceYee C Tee, Stephen J Blake, David J Lynn
Journal of Cellular and Molecular Medicine|April 21, 2009
Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitroStephen J Blake, A Bruce Lyons, Timothy P Hughes
Current Drug Targets|June 6, 2012
RNA interference for viral infectionsStephen J Blake, Fawzi F Bokhari, Nigel A J McMillan
Nature Reviews. Immunology|November 6, 2023
Role of the microbiota in response to and recovery from cancer therapyStephen J Blake, Yochai Wolf, Ben Boursi, et al.
Clinical & Translational Immunology|December 16, 2014
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapiesJing Liu, Stephen J Blake, Mark J Smyth, et al.
Blood|April 10, 2008
Dasatinib suppresses in vitro natural killer cell cytotoxicityStephen J Blake, A Bruce Lyons, Cara K Fraser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2016
Molecular Pathways: Targeting CD96 and TIGIT for Cancer ImmunotherapyStephen J Blake, William C Dougall, John J Miles, et al.
Oncoimmunology|September 14, 2016
Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicityFernando Souza-Fonseca-Guimaraes, Stephen J Blake, Amani Makkouk, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Experimental Hematology|April 24, 2012
Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine AStephen J Blake, Timothy P Hughes, A Bruce Lyons
Current Protocols in Cytometry|April 3, 2013
Flow cytometric analysis of cell division by dilution of CFSE and related dyesA Bruce Lyons, Stephen J Blake, Kathleen V Doherty
FASEB Bioadvances|October 11, 2021
OX40-targeted immune agonist antibodies induce potent antitumor immune responses without inducing liver damage in miceYee C Tee, Stephen J Blake, David J Lynn
Journal of Cellular and Molecular Medicine|April 21, 2009
Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitroStephen J Blake, A Bruce Lyons, Timothy P Hughes
Current Drug Targets|June 6, 2012
RNA interference for viral infectionsStephen J Blake, Fawzi F Bokhari, Nigel A J McMillan
Nature Reviews. Immunology|November 6, 2023
Role of the microbiota in response to and recovery from cancer therapyStephen J Blake, Yochai Wolf, Ben Boursi, et al.
Clinical & Translational Immunology|December 16, 2014
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapiesJing Liu, Stephen J Blake, Mark J Smyth, et al.
Blood|April 10, 2008
Dasatinib suppresses in vitro natural killer cell cytotoxicityStephen J Blake, A Bruce Lyons, Cara K Fraser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2016
Molecular Pathways: Targeting CD96 and TIGIT for Cancer ImmunotherapyStephen J Blake, William C Dougall, John J Miles, et al.
Oncoimmunology|September 14, 2016
Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicityFernando Souza-Fonseca-Guimaraes, Stephen J Blake, Amani Makkouk, et al.
Pageof 4